Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

59 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Radium-223 international early access program: results from the Spanish subset.
Carles J, Méndez MJ, Pinto Á, Sáez MI, Arranz JA, Maroto P, López-Criado P, Mellado B, Donas JG, Hernando S, León L, Del Alba AG, Laínez N, Esteban E, Reynés G, Pérez-Gracia JL, Germà JR, López-Brea M, Pérez-Valderrama B, Moretones C, Castellano D. Carles J, et al. Among authors: mendez mj. Future Oncol. 2018 Jan;14(1):41-50. doi: 10.2217/fon-2017-0297. Epub 2017 Dec 13. Future Oncol. 2018. PMID: 29232987 Clinical Trial.
Experience with Sunitinib in metastatic renal cell carcinoma (mRCC) patients: pooled analysis from 3 Spanish observational prospective studies.
Castellano D, Maroto JP, Espinosa E, Grande E, Bolós MV, Llinares J, Esteban E, González Del Alba A, Climent MA, Arranz JA, Méndez MJ, Fernández Parra E, Antón-Aparicio L, Bayona C, Gallegos I, Gallardo E, Samaniego L, García Donas J. Castellano D, et al. Among authors: mendez mj. Expert Opin Drug Saf. 2018 Jun;17(6):573-579. doi: 10.1080/14740338.2017.1330410. Epub 2017 Aug 28. Expert Opin Drug Saf. 2018. PMID: 28535693 Free article.
Results from the INMUNOSUN-SOGUG trial: a prospective phase II study of sunitinib as a second-line therapy in patients with metastatic renal cell carcinoma after immune checkpoint-based combination therapy.
Grande E, Alonso-Gordoa T, Reig O, Esteban E, Castellano D, Garcia-Del-Muro X, Mendez MJ, García-Donas J, González Rodríguez M, Arranz-Arija JA, Lopez-Criado P, Molina-Cerrillo J, Mellado B, Alvarez-Fernandez C, De Velasco G, Cuéllar-Rivas MA, Rodríguez-Alonso RM, Rodríguez-Moreno JF, Suarez-Rodriguez C. Grande E, et al. Among authors: mendez mj. ESMO Open. 2022 Apr;7(2):100463. doi: 10.1016/j.esmoop.2022.100463. Epub 2022 Apr 8. ESMO Open. 2022. PMID: 35405437 Free PMC article. Clinical Trial.
Phase II open-label study of erlotinib in combination with gemcitabine in unresectable and/or metastatic adenocarcinoma of the pancreas: relationship between skin rash and survival (Pantar study).
Aranda E, Manzano JL, Rivera F, Galán M, Valladares-Ayerbes M, Pericay C, Safont MJ, Mendez MJ, Irigoyen A, Arrivi A, Sastre J, Díaz-Rubio E. Aranda E, et al. Among authors: mendez mj. Ann Oncol. 2012 Jul;23(7):1919-25. doi: 10.1093/annonc/mdr560. Epub 2011 Dec 9. Ann Oncol. 2012. PMID: 22156621 Free article. Clinical Trial.
1-Octadecene as a solvent for ferrofluids for intraocular use.
Tejada P, Méndez MJ, Madero S, Cava C, Barcelo A, Castellano V. Tejada P, et al. Among authors: mendez mj. Eur J Ophthalmol. 1997 Jul-Sep;7(3):288-93. doi: 10.1177/112067219700700315. Eur J Ophthalmol. 1997. PMID: 9352285
Choroidal tubercles with tuberculous meningitis.
Tejada P, Mendez MJ, Negreira S. Tejada P, et al. Among authors: mendez mj. Int Ophthalmol. 1994;18(2):115-8. doi: 10.1007/BF00919251. Int Ophthalmol. 1994. PMID: 7814202
59 results